Pericarditis Management Dr. Cremer, a cardiologist at the Cleveland Clinic Foundation, reviewed the questions patients ask about pericarditis including why the disease develops, will it recur, how is it treated, and what will their treatment duration be. https://t.co/EiK3YDzXvT https://t.co/MrS9WeYn0r

Treatment and Management of Neuropsychiatric Lupus On the first day of ACR State of the Art conference in Orlando, Florida, Dr. Michelle Petri reviewed the treatment and management of neuropsychiatric lupus. https://t.co/csmOHMm8oZ https://t.co/EiWI2e7PF7

ACR 2023 Convergence Brings Back the Poster Hall and 4 Day Meeting ACR Convergence 2023, the annual meeting of the ACR and the world’s premier rheumatology experience, will be held Nov. 10 – 15 at the San Diego Convention Center in San Diego, CA. https://t.co/2yFL5m5Y4f https://t.co/rzTbvRv3nT

QD Clinic - Audience RA Questions from RNL23 Audience Questions & Answers from RNL23 on Rheumatoid Arthritis https://t.co/vh1Tzstbwl https://t.co/IUXfAlzPoE

ICYMI: What to do about pre-clinical RA? Much like the recent ACR Convergence, RheumNow Live’s 2023 conference led with this year’s hot topic of rheumatoid arthritis and especially what to do regarding pre-clinical RA. https://t.co/haxRSMWV3G https://t.co/xci4L0HBGW

PJP Prophylaxis Needed with Steroids and RTX The 2023 EULAR Vasculitis guidelines recommends primary prophylaxis with antibiotics, especially in rheumatic disease patients receiving RTX. https://t.co/eq42bK7MB1 https://t.co/Wk1hOpXanv

RheumThoughts: Giving Good Care in Diversity takes Time Dr. Yvonne Sherrer and second-year fellow Dr. Corin Agoris discuss a case where extended time led to improved patient outcomes. https://t.co/j4QvtBCy6n https://t.co/kECx0yLqJg

Stop RA trail: Plaquenil didn’t prevent RA in patient with pre clinical RA. Kevin Deane #RNL2023 ⁦@RheumNow⁩ https://t.co/0uQshODl1j https://t.co/sXIYyQeemJ

#RNL2023 @RheumNow There are a lot of RA Rx on market now - do we need more? Dr. Brenner: YES Stromal targets like LIF/LIFR, Notch3, cadherin-11 offer upstream benefits for our difficult to treat RA patients that don't respond to tradition cs/bDMARDs https://t.co/xavJrFX84G https://t.co/gAdMU4AgXz

Dr Brenner at #RNL2023 Excellent description on how fibroblasts are major producers of IL-6 producers Clinically presents a target for blocking the fibroblasts, upstream the inflammatory cascade in RA @RheumNow https://t.co/9eQDkEzLBS https://t.co/nOGsjJH7AI

5 year retrospective study of hip replacements (w/ RA, PsA, OA, AS pts), looked at those w perioperative TNFi vs stopped TNFi; showing no differences in outcomes (p = 0.713)> @ last F/U, revision rates were TNFi 2.5%, nonbiologics 3% & 0.8% OA THAs https://t.co/fMKJLyMO6A https://t.co/FofBlxmNEt